Profitability
Weight: 15%
D-
30
- 5yr Avg ROIC -22.7%
- Operating Margin Trend +18.82 pp/yr
TARS
Tarsus Pharmaceuticals, Inc.
AlphaQuality composite grade, weighted for high-growth software businesses.
⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a high-growth software business.
Grade overrides the 23.9 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -36.1%
- 5yr Share-Count CAGR 15.5%
Growth Quality
Weight: 35%
D+
40
- Revenue-Growth Years (5) 2/5
Cash Generation
Weight: 20%
F
0
- 5yr FCF Margin -188.5%
- 5yr FCF/NI Conversion 0.00x
Balance Sheet
Weight: 10%
F
25
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) -6.20x
- Altman Z-Score 8.84
Stability
Weight: 5%
C+
58
- Negative-Revenue Years (5) 2/5
- Piotroski F-Score 5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.1 of 2 gurus held; 1 trimmed; 1 full exit.
- Holders
- 1 -1
- Avg Δ position
- -10.2%
- New buys
- 0
- Full exits
- 1